Literature DB >> 22778323

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

Bruce D Cheson1, John C Byrd, Kanti R Rai, Neil E Kay, Susan M O'Brien, Ian W Flinn, Adrian Wiestner, Thomas J Kipps.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22778323      PMCID： PMC3410400          DOI： 10.1200/JCO.2012.43.3748

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Christian R Geest; Eric Eldering; Betty Y Chang; Joseph J Buggy; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

2.  Optimising the lymphoma response criteria in the era of targeted therapy.

Authors:  Anas Younes; Anton Hagenbeek; Bertrand Coiffier
Journal:  Lancet Oncol       Date:  2011-06-12       Impact factor: 41.316

3.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Authors:  B D Cheson; J M Bennett; M Grever; N Kay; M J Keating; S O'Brien; K R Rai
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

4.  Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.

Authors:  Myron S Czuczman; Aron Thall; Thomas E Witzig; Julie M Vose; Anas Younes; Christos Emmanouilides; Thomas P Miller; Joseph O Moore; John P Leonard; Leo I Gordon; John Sweetenham; Baha Alkuzweny; Deborah M Finucane; Bryan R Leigh
Journal:  J Clin Oncol       Date:  2005-07-01       Impact factor: 44.544

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Authors:  Sabine Ponader; Shih-Shih Chen; Joseph J Buggy; Kumudha Balakrishnan; Varsha Gandhi; William G Wierda; Michael J Keating; Susan O'Brien; Nicholas Chiorazzi; Jan A Burger
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

7.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Authors:  Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

8.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

9.  Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.

Authors:  B D Cheson; J M Bennett; K R Rai; M R Grever; N E Kay; C A Schiffer; M M Oken; M J Keating; D H Boldt; S J Kempin
Journal:  Am J Hematol       Date:  1988-11       Impact factor: 10.047

10.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113
View more
  76 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

2.  Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Authors:  Benjamin L Lampson; Haesook T Kim; Matthew S Davids; Jeremy S Abramson; Arnold S Freedman; Caron A Jacobson; Philippe A Armand; Robin M Joyce; Jon E Arnason; Laura Z Rassenti; Thomas J Kipps; Joshua Fein; Stacey M Fernandes; John R Hanna; David C Fisher; Jennifer R Brown
Journal:  Blood Adv       Date:  2019-04-09

3.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 4.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

Review 5.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

6.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Authors:  Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman
Journal:  N Engl J Med       Date:  2019-08-01       Impact factor: 91.245

7.  Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.

Authors:  John C Byrd; William G Wierda; Anna Schuh; Stephen Devereux; Jorge M Chaves; Jennifer R Brown; Peter Hillmen; Peter Martin; Farrukh T Awan; Deborah M Stephens; Paolo Ghia; Jacqueline Barrientos; John M Pagel; Jennifer A Woyach; Kathleen Burke; Todd Covey; Michael Gulrajani; Ahmed Hamdy; Raquel Izumi; Melanie M Frigault; Priti Patel; Wayne Rothbaum; Min Hui Wang; Susan O'Brien; Richard R Furman
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 9.  Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

10.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.